Try our Advanced Search for more refined results
February 28, 2023
Genentech, Inc. v. Biogen MA, Inc.
Case Number:
3:23-cv-00909
See also:
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
View recent docket activity
Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.
Coverage
-
March 01, 2023
Biogen Owes Patent Royalties For MS Drug, Genentech Says
Biogen Inc. has broken a licensing agreement with Roche Holding AG subsidiary Genentech Inc. by refusing to pay any more royalties from sales of its immunosuppressive drug Tysabri for the treatment of multiple sclerosis and Crohn's disease, according to a lawsuit filed Tuesday in California federal court.
Parties
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Direct access to case information and documents.
- All significant new filings across U.S. federal district courts, updated hourly on business days.
- Full-text searches on all patent complaints in federal courts.
- No-fee downloads of the complaints and so much more!
TRY LAW360 FREE FOR SEVEN DAYS
Already a subscriber? Click here to login